Literature DB >> 3451883

Effects of specific bradycardic agents on exercise-induced regional myocardial dysfunction in dogs.

G Raberger1, G Krumpl, W Schneider, N Mayer.   

Abstract

Alinidine and ULFS 49, two specific bradycardic agents were comparatively investigated with propranolol in a model of exercise-induced regional myocardial contractile dysfunction in dogs. Standardized treadmill exercise resulted in a marked decrease in regional function in the myocardium supplied by the critically stenosed circumflex branch of the left coronary artery. All three drugs prevented exercise-induced myocardial dysfunction. The effect on the exercise-induced increase in heart rate and left ventricular dp/dt, however, suggests different modes of action. Propranolol prevents dysfunction by a marked negative inotropy and negative chronotropy, alinidine by a marked negative chronotropy and moderate negative inotropy, but ULFS 49 prevents dysfunction solely by a marked negative chronotropic effect.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3451883     DOI: 10.1093/eurheartj/8.suppl_l.53

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  3 in total

1.  Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49.

Authors:  C Thollon; C Cambarrat; J Vian; J F Prost; J L Peglion; J P Vilaine
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

2.  Haemodynamic actions of a novel sino-atrial node function modulator, ZENECA ZD7288, in the anaesthetized dog: a comparison with zatebradine, atenolol and nitrendipine.

Authors:  W Rouse; I R Johnson
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

3.  Electropharmacology of the bradycardic agents alinidine and zatebradine (UL-FS 49) in a conscious canine ventricular arrhythmia model of permanent coronary artery occlusion.

Authors:  I Aidonidis; J Brachmann; I Rizos; A Zacharoulis; I Stavridis; P Toutouzas; W Kübler
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.